Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02675439
Title Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Aduro Biotech, Inc.
Indications

lymphoma

Advanced Solid Tumor

Therapies

Ipilimumab + MIW815

MIW815

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.